Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

• YAKUSHIJIN Yoshihiro

  Cancer Center of Ehime University Hospital, Ehime University Graduate School of Medicine

• SHIKATA Hisaharu

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• TAKAOKA Ikue

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• HORIKAWA Tamami

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• TAKEUCHI Kazuhito

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• YAMANOUCHI Jun

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• AZUMA Taichi

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• NARUMI Hiroshi

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

• HATO Takaaki

  Division of Blood Transfusion and Cell Therapy, Ehime University Graduate School of Medicine

• YASUKAWA Masaki

  Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine

収録刊行物

• International journal of clinical oncology

  International journal of clinical oncology 16 (2), 118-124, 2011-04-01

キーワード

• Granulocyte colony-stimulating factors (G-CSF)
• Cost-benefit
• Febrile neutropenia (FN)
• R-CHOP
• Non-Hodgkin lymphoma (NHL)

詳細情報

• CRID: 1573105974853107584
• NII論文ID: 10029366407
• NII書誌ID: AA11086579
• ISSN: 13419625
• 本文言語コード: en
• データソース種別:
  • CiNii Articles